Discovery of 6-Diazo-5-oxo- l -norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,667 · see citing works

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

Ostrom, Q. T., Gittleman, H. R., Fulop, J., Liu, M. B., Blanda, R., Kromer, C. M., Wolinsky, Y., Kruchko, C. A., & Barnholtz‐Sloan, J. S. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov189 · Cited by 2,142 · see citing works

Glutamine addiction: a new therapeutic target in cancer

Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770 · see citing works

Prodrugs: design and clinical applications

Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D.-M., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,645 · see citing works

Glutamine and cancer: cell biology, physiology, and clinical opportunities

Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69600 · Cited by 1,262 · see citing works

Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells

Le, A., Lane, A. N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Zhang, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.009 · Cited by 1,095 · see citing works

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer

Gross, M. I., Demo, S. D., Dennison, J. B., Chen, L., Chernov-Rogan, T., Goyal, B., Janes, J. R., Laidig, G. J., Lewis, E. R., Li, J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0870 · Cited by 1,068 · see citing works

How cancer metabolism is tuned for proliferation and vulnerable to disruption

Schulze, A., & Harris, A. L. (2012) · Nature · doi:10.1038/nature11706 · Cited by 927 · see citing works

Uptake and Metabolism of Plasma Glutamine by the Small Intestine

Windmueller, H. G., & Spaeth, A. E. (1974) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)42329-6 · Cited by 791 · see citing works

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

Weller, M., van den Bent, M. J., Hopkins, K., Tonn, J. C., Stupp, R., Falini, A., Moyal, E. C., Frappaz, D., Henriksson, R., Balañá, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70011-7 · Cited by 754 · see citing works

Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier

Upadhyay, R. K. (2014) · BioMed Research International · doi:10.1155/2014/869269 · Cited by 532 · see citing works

Enzymes involved in the bioconversion of ester-based prodrugs

Liederer, B. M., & Borchardt, R. T. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20542 · Cited by 378 · see citing works

Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment

Tanaka, K., Sasayama, T., Irino, Y., Takata, K., Nagashima, H., Satoh, N., Kyotani, K., Mizowaki, T., Imahori, T., Ejima, Y., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78239 · Cited by 243 · see citing works

Metabolism and action of amino acid analog anti-cancer agents

Ahluwalia, G. S., Grem, J. L., Hao, Z., & Cooney, D. A. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90094-i · Cited by 241 · see citing works

Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes

Hu, X., Stern, H. M., Ge, L., O'Brien, C. L., Haydu, L. E., Honchell, C. D., Haverty, P. M., Peters, B. A., Wu, T. D., Amler, L. C., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0107 · Cited by 218 · see citing works

Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors

Shukla, K. H., Ferraris, D. V., Thomas, A. G., Stathis, M. J., Duvall, B. R., Delahanty, G., Alt, J., Rais, R., Rojas, C. J., Gao, P., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301191p · Cited by 199 · see citing works

Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

Eshleman, J. S., Carlson, B. L., Mladek, A. C., Kastner, B. D., Shide, K. L., & Sarkaria, J. N. (2002) · PubMed · Cited by 197 · see citing works

Glutaminase: A Hot Spot For Regulation Of Cancer Cell Metabolism?

Erickson, J. W., & Cerione, R. A. (2010) · Oncotarget · doi:10.18632/oncotarget.208 · Cited by 155 · see citing works

Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy

Cervantes-Madrid, D., Romero, Y., & Dueñas‐González, A. (2015) · BioMed Research International · doi:10.1155/2015/690492 · Cited by 119 · see citing works

Trypanosoma brucei CTP synthetase: A target for the treatment of African sleeping sickness

Hofer, A., Steverding, D., Chabes, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111139498 · Cited by 116 · see citing works

Structural Basis for the Active Site Inhibition Mechanism of Human Kidney-Type Glutaminase (KGA)

Thangavelu, K., Chong, Q. Y., Low, B. C., & Sivaraman, J. (2014) · Scientific Reports · doi:10.1038/srep03827 · Cited by 108 · see citing works

Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent.

Tougou, K., Nakamura, A., Watanabe, S., et al. (1998) · PubMed · Cited by 100 · see citing works

6-Diazo-5-oxo-L-norleucine, A New Tumor-inhibitory Substance. II.1 Isolation and Characterization2

Dion, H. W., Fusari, S. A., Jakubowski, Z. L., et al. (1956) · Journal of the American Chemical Society · doi:10.1021/ja01594a036 · Cited by 96 · see citing works

Spontaneous tumors, including gastrointestinal neoplasms and malignant melanomas, in the syrian hamster

Fortner, J. G. (1957) · Cancer · doi:10.1002/1097-0142(195711/12)10:6 · Cited by 76 · see citing works

Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells

Lee, Y., Yang, C., Chang, H.-Y., Hsu, H., Chen, I.-S., Chang, H.-S., Lee, C., Lee, J., Kumar, C. R., Qiu, Y., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2173 · Cited by 73 · see citing works

Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas

Earhart, R. H., Amato, D. J., Chang, A. Y.-C., Borden, E. C., Shiraki, M., Dowd, M. E., Comis, R. L., Davis, T. E., & Smith, T. J. (1990) · Investigational New Drugs · doi:10.1007/bf00216936 · Cited by 71 · see citing works

Tumor Metabolism of Malignant Gliomas

Ru, P., Williams, T. M., Chakravarti, A., & Guo, D. (2013) · Cancers · doi:10.3390/cancers5041469 · Cited by 71 · see citing works

Design and evaluation of novel glutaminase inhibitors

McDermott, L. A., Iyer, P. C., Vernetti, L., Rimer, S., Sun, J., Boby, M. L., Yang, T., Fioravanti, M., O’Neill, J., Wang, L., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.009 · Cited by 68 · see citing works

Species-dependent and site-specific intestinal metabolism of ester prodrugs

van Gelder, J., Shafiee, M., Clercq, E. D., PENNINCKX, F. M., den Mooter, G. V., Kinget, R., & Augustijns, P. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00507-x · Cited by 59 · see citing works

Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.

Harding, J. J., Telli, M. L., Münster, P. N., Le, M. H., Molineaux, C. J., Bennett, M. K., Mittra, E., Burris, H. A., Clark, A. S., Dunphy, M. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2512 · Cited by 58 · see citing works

Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma

Lynch, G., Kemeny, N., & Casper, E. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198210000-00014 · Cited by 53 · see citing works

Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON)

Rahman, A., Smith, F. P., Luc, P.-V. T., & Woolley, P. V. (1985) · Investigational New Drugs · doi:10.1007/bf00170760 · Cited by 49 · see citing works

Influence of glutamine on the growth of human glioma and medulloblastoma in culture.

Dranoff, G., Elion, G. B., Friedman, H. S., Campbell, G. L., & Bigner, D. D. (1985) · PubMed · Cited by 49 · see citing works

Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction

Fogal, V., Babić, I., Chao, Y. S., Pastorino, S., Mukthavaram, R., Jiang, P., Cho, Y., Pingle, S. C., Crawford, J. R., Piccioni, D. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2708 · Cited by 45 · see citing works

Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children

Sullivan, M. P., Nelson, J. A., Feldman, S. L., et al. (1988) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00262746 · Cited by 40 · see citing works

SUPPRESSION OF URIC ACID SYNTHESIS IN THE GOUTY HUMAN BY THE USE OF 6-DIAZO-5-OXO-L-NORLEUCINE*

Grayzel, A. I., Seegmiller, J. E., & Love, E. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104057 · Cited by 39 · see citing works

Neurological sequelae induced by alphavirus infection of the CNS are attenuated by treatment with the glutamine antagonist 6-diazo-5-oxo-l-norleucine

Potter, M. C., Baxter, V. K., Mathey, R. W., Alt, J., Rojas, C., Griffin, D. E., & Slusher, B. S. (2015) · Journal of NeuroVirology · doi:10.1007/s13365-015-0314-6 · Cited by 32 · see citing works

The inhibition by 6‐diazo‐5‐oxo‐L‐norleucine of glutamine catabolism of the cultured human lymphoblast

Willis, R. C., & Seegmiller, J. E. (1977) · Journal of Cellular Physiology · doi:10.1002/jcp.1040930308 · Cited by 32 · see citing works

Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma.

Dranoff, G., Elion, G. B., Friedman, H. S., et al. (1985) · PubMed · Cited by 25 · see citing works

Interspecies Differences in the Metabolism of a Multiester Prodrug by Carboxylesterases

Fu, J., Pacyniak, E., Leed, M. G. D., Sadgrove, M. P., Marson, L., & Jay, M. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24632 · Cited by 23 · see citing works

Pharmacokinetics of dapsone and amino acid prodrugs of dapsone.

Pochopin, N. L., Charman, W. N., & Stella, V. J. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07567-1 · Cited by 20 · see citing works

Effects of 6-diazo-5-oxol-norleucine and other tumor inhibitors on the biosynthesis of nicotinamide adenine dinucleotide in mice.

Barclay, R. K., & Phillipps, M. A. (1966) · PubMed · Cited by 20 · see citing works

Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry

Alt, J., Potter, M. C., Rojas, C. J., & Slusher, B. S. (2015) · Analytical Biochemistry · doi:10.1016/j.ab.2015.01.001 · Cited by 18 · see citing works

Studies on prodrugs. IV. Preparation and characterization of N-(5-substituted 2-oxo-1,3-dioxol-4-yl)methyl norfloxacin.

Sakamoto, F., IKEDA, S., Kondo, H., et al. (1985) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.33.4870 · Cited by 18 · see citing works

Alterations in Calcium Metabolism in Cancer Patients Treated with 6-Diazo-5-Oxo-L-Norleucine.

Myers, W. P. L., & Magill, G. B. (1956) · Experimental Biology and Medicine · doi:10.3181/00379727-93-22741 · Cited by 13 · see citing works

The reaction of lithium trimethylsilyldiazomethane with pyroglutamates — a facile synthesis of 6-diazo-5-oxo-norleucine and derivatives

COUTTS, I. G. C., & Saint, R. E. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)00402-x · Cited by 13 · see citing works

Pancreatic cancer: Advances and challenges

Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321 · see citing works

Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion

Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169 · see citing works

Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells

Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131859 · Cited by 456 · see citing works

Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy

Sharma, N. S., Gupta, V. K., Garrido, V. T., Hadad, R., Durden, B. C., Kesh, K., Giri, B., Ferrantella, A., Dudeja, V., Saluja, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127515 · Cited by 203 · see citing works

ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ

Атабекова, Б. Б. (2024) · Habaršy. Pedagogika ġylymdary seriâsy · doi:10.51889/2959-5762.2023.80.4.019

Norleucine: A branched-chain amino acid analog affecting feeding behavior of rats

Tews, J. K., Repa, J. J., & Harper, A. E. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90379-v · Cited by 11 · see citing works

Biosynthesis and Incorporation into Protein of Norleucine by Escherichia coli

Bogosian, G., Violand, B. N., Dorward‐King, E., Workman, W. E., Jung, P., & Kane, J. F. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31291-7 · Cited by 130 · see citing works

Effect of Norleucine and Related Compounds on Growth of the White Rat

Rechcígl, M., Williams, H. H., & Loosli, J. K. (1959) · Nature · doi:10.1038/1831519a0 · Cited by 5 · see citing works

The fate of norleucine as a replacement for methionine in protein synthesis

Barker, D. G., & Bruton, C. J. (1979) · Journal of Molecular Biology · doi:10.1016/0022-2836(79)90531-x · Cited by 30 · see citing works